EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Multisystem Serositis Following Immunotherapy for Metastatic Melanoma: A Case Report

Shraddha Sriraman, Ricky Dylan Frazer, Helen Winter

Case Reports in Oncology · 2026-11-07

DOI: 10.1159/cro/abzag049 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction Immune checkpoint inhibitors have significantly improved outcomes in metastatic melanoma but are associated with a broad spectrum of immune-related adverse events. Serositis is a rare complication of immunotherapy and may present significant diagnostic and therapeutic challenges, particularly when recurrent or refractory to corticosteroid therapy. Case Presentation We report the case of a 40-year-old man with Stage IV BRAF-mutant metastatic melanoma who developed generalised serositis while receiving maintenance nivolumab following combination ipilimumab and nivolumab therapy. Initial presentation occurred 10 months after commencing nivolumab maintenance and was characterised by generalised oedema, pleural effusions, pericardial effusion, ascites, and bowel wall oedema. Extensive investigation excluded infectious and malignant causes, with pleural fluid cytology repeatedly negative for malignant cells. Symptoms initially improved with high-dose corticosteroids but recurred during steroid tapering despite treatment with mycophenolate mofetil and colchicine. Subsequent treatment with infliximab resulted in marked clinical improvement, allowing successful corticosteroid weaning and sustained symptom control. Conclusion To our knowledge, this represents the longest reported follow-up of recurrent immune-mediated multisystem serositis associated with immune checkpoint inhibition and the first report demonstrating successful long-term control with infliximab after failure of corticosteroids, mycophenolate mofetil and colchicine.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →